Income statement, balance sheet and cash flow statement for the last 10 fiscal years, taken from the XBRL data Zivo Bioscience, Inc. files with the SEC in its annual reports.
In USD millions, except per-share amounts. Outflows in the cash flow statement are negative.
Income statement
FY2015
FY2016
FY2017
FY2018
FY2019
FY2020
FY2021
FY2022
FY2023
FY2024
Revenue
0
0
0
0
0
0.02
0
0
0.03
0.16
Cost of revenue
0
0.02
0.11
Gross profit
0
0.01
0.05
Research and development
1.03
0.79
2.38
2.81
2.31
3.75
1.95
2.24
1.38
3.13
General and administrative
0.96
0.83
2.13
1.35
4.08
4.82
6.69
6.49
5.9
10.3
Operating expenses
3.49
6.33
6.13
8.35
8.58
8.65
8.73
7.27
13.4
Operating income
-3.06
-3.49
-6.33
-6.13
-8.35
-8.56
-8.65
-8.73
-7.26
-13.4
Interest expense
-0
-0.04
0.1
0.04
0.01
0.02
Other non-operating income
-2.73
-2.57
-3.71
-8.5
-3.16
-0.55
-0.11
-0.01
Net income
-5.79
-6.06
-10
-14.6
-11.5
-9.11
-8.76
-8.75
-7.78
-13.4
EBITDA
-3.03
-3.47
-6.31
-6.13
-8.35
-8.56
-8.65
EPS, basic
-0.04
-0.05
-0.07
-0.09
-0.04
-0.02
EPS, diluted
-0.04
-0.05
-0.07
-0.09
-0.04
-0.02
-4.60
-4.23
Shares, basic (weighted)
131
134
139
157
276
406
Shares, diluted (weighted)
131
134
139
157
276
406
1.69
3.17
Dividend per share
3.11
Balance sheet
FY2015
FY2016
FY2017
FY2018
FY2019
FY2020
FY2021
FY2022
FY2023
FY2024
Cash and equivalents
0.02
0.51
0.32
0.39
0.35
0.14
8.9
1.8
0.27
1.54
Receivables
0
Other current assets
0.01
0.01
0.02
0.02
0.02
0.03
0.06
0.1
0.15
0.09
Total current assets
0.03
0.52
0.33
0.41
0.37
0.17
8.96
1.9
0.43
1.64
Property, plant and equipment
0.04
0.02
0
0
0
0
0
0
0
Lease right-of-use assets
0
0.05
0.03
0.19
0.1
0
Total assets
0.07
0.74
0.33
0.41
0.37
0.22
8.99
2.12
0.56
1.64
Accounts payable
1.11
0.67
0.54
0.42
1.37
1.56
0.65
0.49
0.99
0.55
Accrued liabilities
2.08
0.4
0.01
0.01
0.1
0.21
0.47
0.4
1.15
1.1
Short-term debt
0
0.11
0
0
Total current liabilities
4.97
11.2
4.56
22.7
8.71
11.4
2.95
2.03
2.76
2.04
Long-term debt
0
0.12
0
0.12
Lease liabilities
0
0.02
0
0.11
0
0
Total liabilities
9.57
14.4
16.6
22.7
8.71
11.5
2.95
2.13
2.76
2.16
Total debt
0
0.11
0
0
Paid-in capital
38.1
40
47.4
56
81.2
87.7
113
116
121
136
Retained earnings
-47.7
-53.8
-63.8
-78.4
-90
-99.1
-107
-116
-124
-137
Shareholders' equity
-9.5
-13.6
-16.3
-22.3
-8.34
-11.3
6.04
-0.01
-2.21
-0.51
Total equity
-9.5
-13.6
-16.3
-22.3
-8.34
-11.3
6.04
-0.01
-2.21
-0.51
Total liabilities and equity
0.07
0.74
0.33
0.41
0.37
0.22
8.99
2.12
0.56
1.64
Shares outstanding
132
137
141
180
413
5.16
9.42
1.57
2.38
3.62
Cash flow statement
FY2015
FY2016
FY2017
FY2018
FY2019
FY2020
FY2021
FY2022
FY2023
FY2024
Net income
-5.79
-6.06
-10
-14.6
-11.5
-9.11
-8.76
8.75
-7.78
-13.4
Depreciation and amortization
0.03
0.03
0.02
0
0
0
0
Stock-based compensation
1.2
2.49
0.09
3.61
1.25
-0.1
-0.3
0.09
1.51
Change in receivables
0
-0
0
Change in payables
-0.02
-0.45
-0.16
0.5
-0.45
Cash from operations
-2.3
-2.54
-4.24
-5.01
-3.71
-2.59
-6.8
-7.1
-5.8
-4.31
Cash from investing
0
0
0
0
0
0
0
0
0
0
Stock issued
0
3.43
2.65
0.4
1.51
0
0.49
5.6
Cash from financing
2.31
3.03
4.05
5.08
3.66
2.38
15.6
0
4.28
5.58
Net change in cash
0.02
0.49
-0.21
8.76
-7.1
-1.52
1.27
Interest paid
0
0
0
0
0
0
0
0.01
0.07
0.02
Income taxes paid
0
0
0
0
0
0
0
0
0
0
Key metrics
Worked out from the statements above. Latest values use the trailing twelve months to September 30, 2025; growth uses fiscal years. Valuation uses the share price of $3.30 on September 25, 2026.
Profitability
Metric
Value
How it is calculated
Gross margin
31.7%
Gross profit / revenue.
Operating margin
-4,046.0%
Operating income / revenue.
Net margin
-4,060.0%
Net income / revenue.
Operating cash flow margin
-1,473.0%
Cash from operations / revenue.
Return on assets (ROA)
-1,517.0%
Net income / average total assets.
R&D / revenue
1,768.0%
Research and development expense / revenue.
Growth
Metric
Value
How it is calculated
Revenue growth, 1y
468.6%
Revenue vs the same period a year earlier. Only from a positive base.
Gross profit growth, 1y
321.6%
Gross profit vs the same period a year earlier. Only from a positive base.
Total assets growth, 1y
195.7%
Total assets vs the same period a year earlier. Only from a positive base.
Total assets CAGR, 3y
-43.2%
Compound annual growth of total assets over 3 fiscal years: (end / start)^(1/3) - 1. Only when both values are positive.
Total assets CAGR, 5y
34.8%
Compound annual growth of total assets over 5 fiscal years: (end / start)^(1/5) - 1. Only when both values are positive.
Share count change, 1y
87.4%
Change in diluted weighted shares vs a year earlier. Negative means buybacks shrank the share count; positive means dilution.
Share count change per year, 5y
-59.1%
Change in diluted weighted shares, per year over 5 years. Negative means buybacks shrank the share count; positive means dilution.
Balance sheet health
Metric
Value
How it is calculated
Current ratio
0.08x
Current assets / current liabilities.
Quick ratio
0.02x
(Cash + short-term investments + receivables) / current liabilities.
Cash ratio
0.02x
(Cash + short-term investments) / current liabilities.
Net income per diluted share, as reported (split-adjusted). Over the last twelve months: the four quarters summed, or net income / latest diluted shares when a quarter has no reported EPS.
Revenue per share
$0.05
Revenue / diluted weighted shares.
Operating cash flow per share
-$0.81
Cash from operations / diluted weighted shares.
Book value per share
-$0.86
Shareholders' equity / shares outstanding (diluted weighted shares when not reported).
Market cap + total debt - cash - short-term investments.
P/S
61.4x
Market cap / revenue.
EV/Sales
61.1x
Enterprise value / revenue.
Earnings yield
-66.1%
Net income / market cap (the inverse of P/E).
What was Zivo Bioscience, Inc.'s revenue in fiscal 2024?
Zivo Bioscience, Inc. reported revenue of $157.2K for fiscal 2024, 468.6% higher than the year before.
Was Zivo Bioscience, Inc. profitable in fiscal 2024?
No. It reported a net loss of $13.4M.
Source: SEC EDGAR XBRL company facts. Where a company tags only year-to-date figures, quarters are worked out as differences. Where a line is not tagged it is left empty, never estimated.